The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb - PubMed (original) (raw)

The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb

T Fujita et al. J Exp Med. 1987.

Abstract

DAF is a 70,000-Mr membrane protein that inhibits the amplification of the complement cascade on the cell surface, and protects cells from damage by complement. The precise mechanism of action of DAF is not entirely clear. Purified DAF was incorporated into the membrane of EAC4b cells. EAC4b2 and EDAF AC4b2 cells were prepared with radiolabeled C2. The same amount of labeled C2 bound to both cells, showing that DAF does not prevent the binding of C2 zymogen to C4b. After adding Cl, the radioactivity of bound C2 dissociated more rapidly from EDAF AC4b cells than from EAC4b cells. In EAC4b cells, bound C2 was converted to C2a, which gradually dissociated into the supernatants. In the DAF-treated cells, on the other hand, a large amount of C2a rapidly appeared in the supernatants and only a small amount of C2a remained on the cells. In a similar experiment using EhuAC4b, DAF on human erythrocyte membrane also dissociated the C2a from the cells. These results were confirmed by hemolytic assay and the accelerated decay of C2a caused the rapid depletion of C2 from the fluid phase. In addition, we found that DAF functions on the alternative pathway C3 convertase, C3bBb in the same manner. Thus, DAF, which associates with C4b and C3b in the membrane, acts on C2a and Bb, but not on intact C2 and B, and dissociates them rapidly from the binding sites, thereby preventing the assembly of the classical and alternative pathways C3 convertases.

PubMed Disclaimer

Cited by

Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.
White J, Lukacik P, Esser D, Steward M, Giddings N, Bright JR, Fritchley SJ, Morgan BP, Lea SM, Smith GP, Smith RA. White J, et al. Protein Sci. 2004 Sep;13(9):2406-15. doi: 10.1110/ps.03455604. Protein Sci. 2004. PMID: 15322283 Free PMC article.
Membrane proteins that protect against complement lysis.
Morgan BP, Meri S. Morgan BP, et al. Springer Semin Immunopathol. 1994;15(4):369-96. doi: 10.1007/BF01837366. Springer Semin Immunopathol. 1994. PMID: 8153873 Review. No abstract available.
Therapeutic uses of recombinant complement protein inhibitors.
Kalli KR, Hsu P, Fearon DT. Kalli KR, et al. Springer Semin Immunopathol. 1994;15(4):417-31. doi: 10.1007/BF01837368. Springer Semin Immunopathol. 1994. PMID: 8153875 Free PMC article. Review.
Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway.
Fujita T, Taira S, Kodama N, Matsushita M, Fujita T. Fujita T, et al. Jpn J Cancer Res. 1995 Feb;86(2):187-92. doi: 10.1111/j.1349-7006.1995.tb03038.x. Jpn J Cancer Res. 1995. PMID: 7730143 Free PMC article.
The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury.
Sakuma M, Morooka T, Wang Y, Shi C, Croce K, Gao H, Strainic M, Medof ME, Simon DI. Sakuma M, et al. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1196-202. doi: 10.1161/ATVBAHA.110.205559. Epub 2010 Mar 18. Arterioscler Thromb Vasc Biol. 2010. PMID: 20299685 Free PMC article.

References

1. Immunochemistry. 1966 Mar;3(2):111-35 - PubMed
1. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2007-11 - PubMed
1. J Exp Med. 1968 Sep 1;128(3):533-51 - PubMed
1. Immunochemistry. 1969 May;6(3):391-403 - PubMed
1. Immunochemistry. 1969 May;6(3):405-19 - PubMed

The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb - PubMed (original) (raw)